A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds ...
Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...
CBS News on MSN8d
Novo Nordisk's obesity-fighting drugs are fattening Denmark's economy while shrinking other sectorsNovo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
Fortune on MSN8d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in DenmarkA more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback